Letter Sequence Other |
---|
EPID:L-2019-NEW-0004, Shine Medical Technologies, LLC Application for an Operating License (Approved, Closed) |
Initiation
- Request, Request, Request, Request, Request, Request, Request, Request, Request, Request, Request, Request, Request, Request, Request, Request
- Acceptance, Acceptance
- Supplement, Supplement, Supplement, Supplement, Supplement, Supplement, Supplement, Supplement, Supplement, Supplement, Supplement, Supplement
Results
Other: ML19235A308, ML19324F963, ML20057F950, ML20114E315, ML20126G523, ML20226A262, ML21029A103, ML21053A261, ML21089A228, ML21089A334, ML21096A250, ML21130A314, ML21145A060, ML21161A115, ML21209A997, ML21210A438, ML22042A018, ML22075A331, ML22075A336, ML22095A067, ML22124A073, ML22125A040, ML22152A108, ML22187A134, ML22206A208, ML22216A112, ML22220A261, ML22308A233, ML22322A212, ML22322A223, ML22347A177, ML22347A214, ML22348A067, ML22348A070, ML22348A072, ML23006A185
|
MONTHYEARML19211C0442019-07-17017 July 2019 Shine Medical Technologies, LLC Application for an Operating License Project stage: Request ML19211C1432019-07-17017 July 2019 Shine Medical Technologies, LLC Application for an Operating License Project stage: Request ML19235A3082019-09-0505 September 2019 Shine Medical Technologies, LLC - Cover Letter for Notice of Receipt and Availability of Operating License Application Project stage: Other ML19276D4112019-10-0808 October 2019 Shine Medical Technologies, LLC - Acceptance for Docketing Letter Project stage: Acceptance Review ML19276D4092019-10-0808 October 2019 Shine Medical Technologies, LLC - Operating License Application Acceptance Review Results Project stage: Request ML19276D4102019-10-0808 October 2019 Shine Medical Technologies, LLC - Acceptance for Docketing Federal Register Notice Project stage: Acceptance Review ML19337A2752019-11-14014 November 2019 Shine Medical Technologies, LLC Supplement 1 to Final Safety Analysis Report Project stage: Request ML19353C6872019-12-19019 December 2019 Environmental Site Audit Regarding Shine Medical Technologies, LLC - Proposed Medical Isotope Production Facility Project stage: Request ML19324F9622020-01-0202 January 2020, 6 January 2020 Shine Medical Technologies, LLC - Notice of Opportunity for Hearing and Petition for Leave to Intervene Project stage: Request ML19324F9632020-01-0202 January 2020 Shine Medical Technologies, LLC - Cover Letter for Notice of Opportunity for Hearing and Petition for Leave to Intervene Project stage: Other ML20057F9502020-03-0606 March 2020 Shine Medical Technologies, LLC - Instrumentation and Control Regulatory Audit Plan Project stage: Other ML20105A2952020-03-27027 March 2020 Shine Medical Technologies, LLC, Supplement 2 to License Application, Rev.2 to Final Safety Analysis Report Project stage: Supplement ML20114E3152020-04-30030 April 2020 Shine Medical Technologies, LLC - Operating License Application Technical Review Schedule Project stage: Other ML20126G5232020-05-0707 May 2020 Shine Medical Technologies, LLC - Regulatory Audit Plan Related to Electrical Power Systems Project stage: Other ML20226A2622020-08-14014 August 2020 Shine Medical Technologies, LLC - Accident Analysis and Criticality Safety Audit Plan Project stage: Other ML20255A0272020-08-28028 August 2020 Shine Medical Technologies, LLC Operating License Application Response to Request for Additional Information and Supplement No. 3 Project stage: Supplement ML21309A0192020-10-16016 October 2020 Shine Medical Technologies, LLC - Request for Additional Information Related to Chapters 2, 3, and 8 Project stage: RAI ML20311A1242020-10-30030 October 2020 Shine Medical Technologies, LLC, Operating License Application Supplement No. 4 Submittal of a Revision to the Shine Physical Security Plan Project stage: Supplement ML21309A0232020-11-10010 November 2020 Shine Medical Technologies, LLC - Request for Additional Information Related to Chapters 6 and 13 Project stage: RAI ML20325A0262020-11-13013 November 2020 Submittal of a Mark-Up to the Draft NRG-Proposed SHINE-Specific Security Measures Project stage: Request ML20357A0862020-12-10010 December 2020 Enclosure 1 - Final Safety Analysis Report Change Summary Project stage: Request ML21011A2242020-12-15015 December 2020 Shine Medical Technologies, LLC - Operating License Application Supplement No. 6 and Response to Request for Additional Information Project stage: Supplement ML20352A2252020-12-18018 December 2020 Shine Environmental RAIs - Cumulative Impacts Project stage: RAI ML21309A0442021-01-27027 January 2021 Shine Medical Technologies, LLC - Request for Additional Information Related to Chapters 9 and 11 Project stage: RAI ML21019A1592021-01-27027 January 2021 Public Meeting Summary January 12 2021 Project stage: Meeting ML21029A1032021-01-29029 January 2021 Enclosure 1 - Response to Final Safety Analysis Report Chapters 2, 3, and 8 Requests for Additional Information Project stage: Other ML21029A1022021-01-29029 January 2021 Shine Medical Technologies, LLC Operating License Application Response to Request for Additional Information Project stage: Response to RAI ML21029A0382021-01-29029 January 2021 Request for Exemption from Criticality Accident Alarm System Monitoring Requirements for the Shine Irradiation Unit Cells and Material Staging Building Project stage: Request ML21057A0052021-02-26026 February 2021 Shine Medical Technologies. LLC Application for an Operating License Commitment Change Related to the Submission of a Revision to the Technical Specifications Project stage: Request ML21053A2612021-03-11011 March 2021 Shine Medical Technologies - Geotechnical Audit Plan Project stage: Other ML21075A0122021-03-16016 March 2021 Shine Medical Technologies, LLC - Application for an Operating License, Revision 1 of Shine Response to Request for Additional Information 2.4-1 Project stage: Response to RAI ML21095A2142021-03-23023 March 2021 Shine Medical Technologies, LLC, Revisions to Final Safety Analysis Report, Chapter 6, Engineered Safety Features Project stage: Request ML21095A2222021-03-23023 March 2021 Shine Medical Technologies, LLC, Revisions to Final Safety Analysis Report, Chapter 5, Cooling Systems Project stage: Request ML21095A2292021-03-23023 March 2021 Shine Medical Technologies, LLC, Response to Request for Additional Information and Supplement No. 7 Project stage: Supplement ML21095A2352021-03-23023 March 2021 Shine Medical Technologies, LLC, Cover Letter for Response to Request Tor Additional Information and Supplement No. 7 Project stage: Supplement ML21089A3342021-04-0707 April 2021 Shine Medical Technologies, LLC - Summary of Audit Related to Geotechnical Topics Project stage: Other ML21089A0012021-04-0808 April 2021 Shine Medical Technologies, LLC - Request for Additional Information Related to Meteorological Data, Cooling Systems, and Physical Security Project stage: RAI ML21096A2502021-04-0808 April 2021 Shine Medical Technologies - Fire Protection Audit Plan Project stage: Other ML21106A1362021-04-16016 April 2021 Shine Medical Technologies, LLC Application for an Operating License Revision 1 of Shine Response to Request for Additional Information 3.4-6 Project stage: Response to RAI ML21089A2282021-04-21021 April 2021 Shine Medical Technologies, LLC - Physical Security Plan Audit Summary Project stage: Other ML21130A3132021-05-12012 May 2021 Shine Medical Technologies, LLC - Instrumentation and Control Systems Audit Topics Enclosure 2 Project stage: Request ML21130A3142021-05-12012 May 2021 Shine Medical Technologies, LLC - Instrumentation and Control Systems Audit Plan Project stage: Other ML21145A0602021-06-0202 June 2021 Shine Medical Technologies - Ch 6 8 13 and Exemption RAI Project stage: Other ML21161A1162021-06-10010 June 2021 Shine Medical Technologies, LLC - Cyber Security Audit Plan W/ 2 Encl Project stage: Request ML21161A1152021-06-10010 June 2021 Shine Medical Tech Ltr - Cyber Security Audit Plan Enclosure 1 Project stage: Other ML21162A3182021-07-0101 July 2021 Shine Medical Technologies, LLC - Request for Additional Information Related to Fire Protection Project stage: RAI ML21172A1952021-07-0101 July 2021 Shine Medical Technologies, LLC - Request for Additional Information Related to Instrumentation and Control Systems Project stage: RAI ML21208A1352021-07-27027 July 2021 Shine Medical Technologies, LLC Application for an Operating License Response to Request for Additional Information Project stage: Response to RAI ML21209A9972021-08-0303 August 2021 Shine Medical Technologies, LLC - Update to Operating License Application Technical Review Schedule Project stage: Other ML21210A4382021-08-13013 August 2021 Shine Medical Technologies, LLC - Cyber Security RAI Project stage: Other 2020-08-14
[Table View] |
|
---|
Category:E-Mail
MONTHYEARML23124A0472023-05-0202 May 2023 NRR E-mail Capture - Planned Issuance of Shine Technologies LLC Construction Permit Amendment No. 4 ML23114A0832023-04-20020 April 2023 NRR E-mail Capture - Shine Technologies, LLC - Environmental Assessment for Construction Permit Amendment No. 4 ML23041A0402023-02-0909 February 2023 NRR E-mail Capture - Request for Additional Information Construction Permit (Cp), License Amendment Request (LAR) ML23006A1862023-01-0606 January 2023 NRR E-mail Capture - Acceptance Review - Shine Amendment Request to CPMIF-001 for SNM ML22357A0432022-12-22022 December 2022 NRR E-mail Capture - RCI for FSAR and TS Updates ML22348A0672022-12-0101 December 2022 Shine Technologies, LLC - Request for Confirmatory Information Related to Instrumentation and Control Systems ML22348A0702022-11-10010 November 2022 (E-MAIL) Shine Medical Technologies, LLC Request for Confirmatory Information Related to Instrumentation and Control Systems ML22348A0722022-10-28028 October 2022 (Email) Shine Medical Technologies, LLC Request for Confirmatory Information Related to Accident Analysis ML22319A2262022-10-13013 October 2022 Email State of Wisconsin-SHINE Medical Technologies, LLC - Environmental Assessment for Construction Permit Amendment ML23006A1852022-09-19019 September 2022 NRR E-mail Capture - Shine Medical Technologies, LLC - Request for Confirmatory Information Related to Phased Startup Operations ML21335A0372021-12-0202 December 2021 EMAIL-Notice to the State of Wisconsin for the Planned Issuance of Shine Medical Technologies Construction Permit Amendment .Pdf ML21336A1932021-12-0202 December 2021 EMAIL-SHINE Amendment - Changes to Construction Permit No. CPMIF-001 for Possession and Receipt of Radioactive Materials ML20202A6082020-06-29029 June 2020 Shine Medical Technologies, LLC - Draft Fire Protection Audit Topic E-mail Transmission ML20148M2792020-05-26026 May 2020 Email - Issuance of Request for Additional Information Related to the Shine Medical Technologies, LLC Operating License Application ML20031D5572020-01-24024 January 2020 Response to Winnebago Tribe of Nebraska Shine Scoping Request NRC-2019-0017, Scoping Comment from M. Sedlacek, EPA Shine Medical Technologies, LLC Operating License Review2019-12-0505 December 2019 Scoping Comment from M. Sedlacek, EPA Shine Medical Technologies, LLC Operating License Review ML17031A4392017-01-26026 January 2017 Review of Shine SGI Protection Program Procedures (E-mail) ML15298A0022015-10-22022 October 2015 NRR E-mail Capture - (External_Sender) FW: Shine Medical Technologies Water Quality Certification ML15267A8022015-09-23023 September 2015 Shine Draft SER Email Transmitting Chapters 1-15 and References ML15244A5062015-08-27027 August 2015 E-mail from Steven Lynch to Jim Costedio Transmitting Draft Request for Additional Information Supporting Shine PSAR ML14325A5432014-11-21021 November 2014 NRR E-mail Capture - Licensed Material ML14209B0632014-07-24024 July 2014 E-mail Correspondence - Shine Preliminary Safety Analysis Report, Revised Draft Request for Additional Information ML13221A3932013-08-0808 August 2013 Draft Shine Response to Proposed Action Request #5 ML13210A0032013-07-24024 July 2013 NRR E-mail Capture - 7/30 Tour Route ML13186A0202013-07-0303 July 2013 NRR E-mail Capture - Draft Environmental Site Audit Needs 2023-05-02
[Table view] Category:Request for Additional Information (RAI)
MONTHYEARML23041A0402023-02-0909 February 2023 NRR E-mail Capture - Request for Additional Information Construction Permit (Cp), License Amendment Request (LAR) ML22348A0672022-12-0101 December 2022 Shine Technologies, LLC - Request for Confirmatory Information Related to Instrumentation and Control Systems ML22348A0702022-11-10010 November 2022 (E-MAIL) Shine Medical Technologies, LLC Request for Confirmatory Information Related to Instrumentation and Control Systems ML22348A0722022-10-28028 October 2022 (Email) Shine Medical Technologies, LLC Request for Confirmatory Information Related to Accident Analysis ML22105A1102022-08-26026 August 2022 Shine Medical Technologies LLC - Request for Additional Information Related to the OGC Review of Phrase Approach ML22063A7042022-05-0606 May 2022 Shine Medical Technologies, LLC - Request for Additional Information Related to the Phased Approach ML22088A1662022-04-18018 April 2022 Shine Medical Technologies, LLC - Request for Additional Information Related to the Process Integrated Control System ML22012A2032022-01-27027 January 2022 Shine Medical Technologies, LLC - Request for Additional Information Related to the Neutron Flux Detection System ML22007A2172022-01-11011 January 2022 Shine Medical Technologies, LLC - Request for Additional Information Related to Instrumentation and Control Systems ML21355A3602021-12-23023 December 2021 Shine Medical Technologies, LLC - Request for Additional Information Related to Radiation Damage ML21280A3382021-10-22022 October 2021 Shine Medical Technologies, Llc Request for Additional Information Related to Operator Training and Requalification Program ML21252A7532021-09-29029 September 2021 Shine Medical Technologies, LLC - Request for Additional Information Related to Instrumentation and Control Systems ML21210A4382021-08-13013 August 2021 Shine Medical Technologies, LLC - Cyber Security RAI ML21162A3182021-07-0101 July 2021 Shine Medical Technologies, LLC - Request for Additional Information Related to Fire Protection ML21172A1952021-07-0101 July 2021 Shine Medical Technologies, LLC - Request for Additional Information Related to Instrumentation and Control Systems ML21173A0122021-06-28028 June 2021 Shine Medical Technologies - Structural RAIs ML21145A0602021-06-0202 June 2021 Shine Medical Technologies - Ch 6 8 13 and Exemption RAI ML21089A0012021-04-0808 April 2021 Shine Medical Technologies, LLC - Request for Additional Information Related to Meteorological Data, Cooling Systems, and Physical Security ML21309A0442021-01-27027 January 2021 Shine Medical Technologies, LLC - Request for Additional Information Related to Chapters 9 and 11 ML20352A2252020-12-18018 December 2020 Shine Environmental RAIs - Cumulative Impacts ML21309A0232020-11-10010 November 2020 Shine Medical Technologies, LLC - Request for Additional Information Related to Chapters 6 and 13 ML21309A0192020-10-16016 October 2020 Shine Medical Technologies, LLC - Request for Additional Information Related to Chapters 2, 3, and 8 ML20148M2802020-05-26026 May 2020 Request for Additional Information Related to Shine Medical Technologies, LLC Operating License Application (Enclosure) ML20092L5922020-04-14014 April 2020 Letter to G. Piefer Clarification on Request for Additional Information Responses for Environmental Review of the Shine Medical Technologies, LLC - Proposed Medical Isotope Production Facility Operating License Application (Dkt No. 50-608) ML19024A5302019-02-13013 February 2019 Shine Medical Technologies, Inc. - Request for Additional Information Regarding the Application for Indirect License Transfer and Conforming Amendment ML17031A4432017-02-0606 February 2017 Shine Medical Technologies, Inc. - Request for Additional Information Regarding Safeguards Information Protection Program ML17031A4402017-01-26026 January 2017 Draft Request for Additional Information Regarding Shine SGI Protection Program ML17031A4392017-01-26026 January 2017 Review of Shine SGI Protection Program Procedures (E-mail) ML15259A1642015-09-24024 September 2015 Shine Medical Technologies, Inc., - Request for Additional Information Regarding Application for Construction Permit ML15244A7712015-08-27027 August 2015 Draft Request for Additional Information Shine Medical Technologies, Inc. Preliminary Safety Analysis Report Supporting a Construction Permit Application ML15099A6072015-04-15015 April 2015 Shine Medical Technologies, Inc., - Request for Additional Information Regarding Application for Construction Permit(Tac Nos. MF2305, MF2307, and MF2308) ML15055A1162015-03-25025 March 2015 Shine Medical Technologies, Inc., - Request for Additional Information Regarding Application for Construction Permit ML15005A4072015-01-0606 January 2015 Shine Medical Technologies, Inc., Request for Additional Information Regarding Application for Construction Permit ML14195A1592014-09-19019 September 2014 Shine Medical Technologies, Inc. - Request for Additional Information Regarding Application for Construction Permit ML14209B0642014-07-24024 July 2014 Shine Revised Draft Request for Additional Information Regarding Application for Construction Permit ML13231A0412013-09-11011 September 2013 Requests for Additional Information Shine 2023-02-09
[Table view] |
Text
From: Michael Balazik To: Jeffrey Bartelme Cc: Josh Borromeo; Holly Cruz
Subject:
Request to Confirm Information FSAR Chapter 13, "Accident Analysis" Date: Friday, October 28, 2022 11:36:00 AM
Dear Dr. Piefer:
By letter dated July 17, 2019 (Agencywide Documents Access and Management System Accession No. ML19211C044), as supplemented, SHINE Medical Technologies, LLC (SHINE) submitted to the U.S. Nuclear Regulatory Commission (NRC) an operating license application for its proposed SHINE Medical Isotope Production Facility in accordance with the requirements contained in Title 10 of the Code of Federal Regulations (10 CFR) Part 50, Domestic Licensing of Production and Utilization Facilities.
During the NRC staffs review of SHINEs operating license application, questions have arisen for which confirmatory information is needed. The enclosed request for confirmatory information (RCI) identifies information needed for the NRC staff to continue its review of the SHINE final safety analysis report, submitted in connection with the operating license application, and prepare a safety evaluation report. The specific technical area of the SHINE operating license application covered by these RCIs is Chapter 13, Accident Analysis.
It is requested that SHINE provide responses to the enclosed RCI within 30 days from the date of this letter. To facilitate a timely and complete response to the enclosed RCI, the NRC staff is available to meet with SHINE to clarify the scope of information and level of detail expected to be included in the RCI response. SHINE may coordinate the scheduling and agendas for any such meetings with the responsible project manager assigned to this project.
In accordance with 10 CFR 50.30(b), Oath or affirmation, SHINE must execute its response in a signed original document under oath or affirmation. The response must be submitted in accordance with 10 CFR 50.4, Written communications. Information included in the response that is considered sensitive or proprietary, that SHINE seeks to have withheld from the public, must be marked in accordance with 10 CFR 2.390, Public inspections, exemptions, requests for withholding. Any information related to safeguards should be submitted in accordance with 10 CFR 73.21, Protection of Safeguards Information: Performance Requirements. Following receipt of the confirmatory information, the NRC staff will continue its evaluation of the subject chapters and technical areas of the SHINE operating license application.
As the NRC staff continues its review of SHINEs operating license application, additional RCIs for other chapters and technical areas may be developed. The NRC staff will transmit any further questions to SHINE under separate correspondence.
If SHINE has any questions, or needs additional time to respond to this request, please contact me at 301-415-2856, or by electronic mail at Michael.Balazik@nrc.gov.
OFFICE OF NUCLEAR REACTOR REGULATION REQUEST FOR CONFIRMATORY INFORMATION REGARDING OPERATING LICENSE APPLICATION FOR SHINE MEDICAL TECHNOLOGIES, LLC CONSTRUCTION PERMIT NO. CPMIF-001 SHINE MEDICAL ISOTOPE PRODUCTION FACILITY DOCKET NO. 50-608 By letter dated July 17, 2019 (Agencywide Documents Access and Management System Accession No. ML19211C044), as supplemented, SHINE Medical Technologies, LLC (SHINE) submitted to the U.S. Nuclear Regulatory Commission (NRC) an operating license application for its proposed SHINE Medical Isotope Production Facility in accordance with the requirements contained in Title 10 of the Code of Federal Regulations (10 CFR) Part 50, Domestic Licensing of Production and Utilization Facilities.
During the NRC staffs review of the SHINE operating license application, and the review of documents during the audit, questions have arisen for which confirmatory information is needed. This request for confirmatory information (RCI) identifies information needed for the NRC staff to continue its review of the SHINE final safety analysis report (FSAR), submitted as part of the operating license application, and prepare a safety evaluation report. Specific chapters and technical areas of the SHINE operating license application covered by this RCI include the following:
- Chapter 13, Accident Analysis Applicable Regulatory Requirements and Guidance Documents Section 50.34, Contents of applications; technical information, paragraph (b) of 10 CFR states, in part, that [t]he final safety analysis report shall include information that describes the facility, presents the design bases and the limits on its operation, and presents a safety analysis of the structures, systems, and components and of the facility as a whole. Section 50.34, subparagraph (b)(4) of 10 CFR states, in part, that final analysis and evaluation of the design and performance of structures, systems, and components with the objective stated in paragraph (a)(4) of this section and taking into account any pertinent information developed since the submittal of the preliminary safety analysis report.
RCI 13-1 For the accident-specific materials-at-risk described in SHINE FSAR Section 13a2.2, Accident Analysis and Determination of Consequences, confirm the following the following information:
For the accident specific material-at-risk (MAR) for the maximum hypothetical accident, the analysis deterministically assumes that 25 percent of iodine in the TSV solution in initially within the TSV offgas system (TOGS). It is
assumed that the iodine in solution is predominantly volatile and that aqueous to gas partitioning occurs rapidly, causing 100% of the iodine inventory to be released to TOGS post shutdown. SHINE conservatively assumes that 100% of the safety-basis MAR is released.
RCI 13-2 For the identification of control volumes and leakage paths in SHINE FSAR Section 13a2.2, confirm the following information:
SHINE identified the control volumes, leakage paths, and heat sinks that define the model geometry. The control volumes used in the analysis include the source volume, the building volume, and the environment.
Leakage paths are treated as junctions between the control volumes.
The analysis considers each part of the facility as a fixed volume that the material is free to disperse into. Dispersion within these volumes is assumed to be instantaneous. Each volume is connected by one or more junctions which allows flow in one direction at a volumetric flow rate, either pressure-driven or constant. Counter-current flow, or flow back into the previous control volume, is not considered in this calculation.
The SHINE-identified scenarios can be organized into four leak-path combinations which include: release location, initial confinement, secondary confinement, and release to environment. These leak-path combinations are:
- 1. Confinement by IU Cell or concrete cell -> IF building -> environment;
- 2. Confinement by glovebox -> IF building -> environment;
- 3. Confinement by hot cell -> RPF building -> environment; and
- 4. Confinement by concrete vault -> RPF building -> environment.
RCI 13-3 For the derivation of iodine reduction factors in SHINE FSAR Section 13a2.2, confirm the following the following information:
SHINE utilized the following model and guidance to perform this analysis:
- Iodine partitioning was calculated using equations based on the definitions found in NUREG/CR-5950, Iodine Evolution and pH Control.
- Bursting bubble aerosols are treated using a linear relationship between entrainment coefficients and the volumetric flow rate with entrainment coefficients consistent with the small amount of dissolved materials present in the target solution.
- Spray and free-fall aerosols use a constant airborne release fraction found in NUREG/CR-6410.
- Radiolysis was treated as either an instantaneous release of hydrogen or as entrainment with source generation based on decay power inputs for long-term problems.
All scenarios containing iodine use isotope reduction factors that account for
TOGS running during normal operations. Scenarios that are downstream from the IU cell take an additional removal factor of iodine due to the operation of the TOGS during the post-irradiation dump tank hold time.
SHINE calculation, CALC-2018-0048, Appendix B, Justification for Treatment of Iodine, contains the justification for the removal factors that are utilized in this calculation as well as the isotope-specific reduction factors.
The table below provides a list for each DBA scenarios which assumes iodine removal factors for the IU, the dump tank, or both.
Design-Basis Accident Scenarios Utilizing Iodine Removal Factors Irradiation Dump Tank Scenario Reduction Reduction Number Factor Factor 1a x 1b x 3 x 9a x x 9b x x 10 x 11 x x 12 x x 14 x x RCI 13-4 For the quantification of leak rates between volumes in SHINE FSAR Section 13a2.2, confirm the following information:
SHINE defined leakage rates between volumes driven by pressure, gas density differences, and barometric breathing. The outcome of this sub-step as expressions for removal rates. The gas pressure in each volume is determined using a combination of conservation laws for mass and energy, temperature-dependent specific heats, and the ideal gas law. Pressure-driven flow through each junction was calculated using the standard compressible flow equation for pressure-driven flow. Pressure-driven flow through shielding cover plug gaps was calculated using the equation for plane Poiseuille flow. In the absence of pressure-driven flow, counter-current flow was assumed to be induced and was calculated based on the difference in pressure from one side of the cover plug to the other. There is no assumed flow from the IF to the RPF or vice versa; all material in the IF or RPF control volumes exits the SHINE facility to the environment.
RCI 13-5 For the quantification of removal mechanisms in SHINE FSAR 13a2.2, confirm the following information:
SHINE established expressions for removal rates of radionuclides.
Specifically, iodine adsorption, non-volatile aerosol deposition, and removal by filters along flow paths. Removal by aerosol settling was evaluated using Stokes law and the calculated equilibrium particle size for a hygroscopic particle. Consideration of removal by filters in the accident flow paths was
done by assigning decontamination factors for noble gases, iodine, and aerosols to each filter. Removal due to barometric breathing was based on an analysis of the peak-to-peak magnitude of environmental pressure fluctuations. Eight years of pressure data were collected and analyzed to provide a bounding estimate of the barometric breathing flow rate for the facility.
RCI 13-6 For assessing meteorological conditions in SHINE FSAR Section 13a2.2, confirm the following:
The x/Q values are calculated for periods of 0-2 hours, 0-8 hours, 8-24 hours, 1-4 days, and 4-30 days following the effluent release.
The control room atmospheric dispersion x/Q values utilized in the SHINE accident analysis are reported in CALC-2018-0048 Rev. 6, Table 3-1, 95th Percentile Site Boundary x/Q values, are as follows:
Time Bin (hours)
Locations 0-2 2-8 8-24 24-96 96-720 Control Room Public x/Q 1.40E-2 1.09E-2 4.61E-3 2.99E-3 2.33E-3 Values (s/m3)
RCI 13-7 For operator radiological consequences assumptions in SHINE FSAR Section 13a.2.2, confirm the following:
The volume of the control room is conservatively estimated to be 350 m3 based on the dimensions of the control room minus estimated sizes of the equipment in the control room. SHINE assumes no cross contamination from IF and RPF as the control room is not part of the radiologically control area. Therefore, the radionuclide flow path from the material at risk source to the control room is accident-dependent but generally flows to the environment to the facility ventilation system intake (FVZ4) using the control room atmospheric c/Q values. The facility ventilation zone four system is responsible for delivering air to the control room and many other rooms in the non-radiologically controlled area of the SHINE facility where approximately 20% of the FVZ4 inlet flow is delivered to the control room. The FVZ4 is assumed to continue running after all initiating events as it is not safety-related. Material that reaches the control room are assumed to instantaneously diffuses within the control room volume. The ventilation system is assumed to continue running after all initiating events for a period of 30 days. The breathing rate for control room operators is 3.50E-04 m3/s based on those stated in RG 1.195 for the duration of the scenario. Control room occupancy factors are sourced from RG 1.195 item 4.2.6 as described below:
Control Room Occupancy Factors
0-24 hours 24-96 hours96-720 hours Occupancy Factor 1.0 0.6 0.4 RCI 13-8 For public radiological consequences assumptions in SHINE FSAR Section 13a.2.2, confirm the following:
The public radiological consequences are computed by modeling the radionuclide flow path from the material at risk source to the environment in combination with the siting public atmospheric c/Q values over a 30-day period. The breathing rate for control room operators is 3.50E-04 m3/s based on those stated in RG 1.195 for the duration of the scenario.
RCI 13-9 TS 5.5.1, Nuclear Safety Program, states, in part, the following:
The safety program accomplishes these goals through development and maintenance of the accident analysis, identification of safety-related controls credited for the prevention or mitigation of accidents, and establishment of programmatic administrative controls to ensure reliability of the credited controls.
Confirm that TS 5.5.1 will ensure that the SHINE Safety Analysis and its supporting documentation remain accurate and current, including prompt updates of the SHINE Safety Analysis and its supporting documentation when a change is made to the facility, operations, or FSAR descriptions.
Best Regards, Michael Balazik Project Manager/Inspector Non-Power Production and Utilization Facility Licensing Office of Nuclear Reactor Regulation U.S. Nuclear Regulatory Commission Michael.Balazik@nrc.govl Tel: (301) 415-2856